TY - JOUR 
A1 - Herrero Rivera, Daniel
AU - Garrigós Vacas, Carmen
AU - Marcos Kovandzic, Laura
AU - Puente Vazquez, Javier
AU - Alonso, Lucía A.
AU - Mellado González, Begoña
AU - Grande, Enrique
AU - Luque Caro, Raquel
AU - Virizuela Echaburu, Juan A.
AU - Rodríguez Moreno, Juan F.
AU - Etxebarria, Ainara A.
AU - Rodríguez Antona, Antona
AU - Durán, Ignacio
T1 - Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel
Y1 - 2022
SN - 1462-2416
UR - http://hdl.handle.net/11268/11560
AB - Background: The aim of this study was to evaluate the impact of certain single-nucleotide polymorphisms (SNPs) in cabazitaxel activity and toxicity in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: 56 SNPs in five genes (CYP3A4, CYP3A5, ABCB1, TUBB1 and CYP2C8) were genotyped in 67 mCRPC patients and their correlation with outcomes analyzed. Results:TUBB1-rs151352 (hazard ratio: 0.52) and CYP2C8-rs1341164 (hazard ratio: 0.53) were associated with better overall survival, and CYP2C8-rs1058932 with biochemical progression (odds ratio: 6.60) in multivariate analysis. ABCB1-rs17327624 correlated with severe toxicity ≥ grade 3 (odds ratio: 8.56) and CYP2C8-rs11572093 with asthenia (odds ratio: 8.12). Conclusion: Genetic variants in mCRPC patients could explain different outcomes with cabazitaxel. Nonetheless, the small sample size and the high number of SNPs analyzed mean that the results are only hypothesis-generating and require further validation.
KW - Neoplasias de la próstata
KW - Farmacocinética
KW - Genética
KW - Cáncer
KW - Farmacología
LA - eng
ER -